Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.

The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.

Long-term diabetes is linked to lower prostate cancer risk.

The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

The meeting highlighted promising genetic treatments for male fertility issues but noted concerns about certain cancer risks and ICSI safety.

Selenium supplements do not prevent cancer and may increase certain health risks.

Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.

Finasteride reduces prostate cancer risk but may increase high-grade cancer risk.

Finasteride reduces prostate cancer risk but may increase aggressive cancer risk slightly.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.

Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.

Finasteride reduces low-grade prostate cancer but may not be beneficial overall.

There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.

Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.

Finasteride, a hair loss drug, may cause sexual dysfunction and depression, but these effects are usually temporary and the drug is generally safe. More research is needed.

Male pattern baldness is common, treatable, and may be linked to heart disease and prostate cancer.

Finasteride may reduce prostate tumor cell invasion and spread.

Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

5-alpha reductase inhibitors do not increase hip fracture risk.

Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.